Study Of Candonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer Clinical Trial

Official title:

A Single-arm, Multicenter, Phase II Study to Evaluate Candonilimab（AK104） Combined With Radiotherapy For The Treatment of Locally Advanced Cervical Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05687851
• Other study ID #: CQGOG010
• Status: Recruiting
• Phase: Phase 2
• Start date: December 29, 2022
• Est. completion date: December 2026

Study information

• Verified date: December 2022
• Source: Chongqing University Cancer Hospital
• Contact: Xingtao Long, MD
• Phone: +8602365075619
• Email: longxingtao2009[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Candonilimab（AK104）is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4. This is a single-arm, multicenter, open-label, phase II study, the purpose of this study is to evaluate the efficacy and safety of candonilimab plus radiotherapy in participants with locally advanced cervical cancer who do not tolerate chemotherapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 33
• Est. completion date: December 2026
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Able to understand and voluntarily sign written informed consent.

2. Women aged =18 years at the time of study entry.

3. Eastern Cancer Cooperative performance status (ECOG PS) score of 0 or 1.

4. Life expectancy =12 weeks.

5. Participants' intolerance to chemotherapy regimens.

6. Histologically confirmed cervical cancer.

1. Histologically-confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix;

2. Not receiving systemic anti-tumour therapy (including but not limited to radiotherapy, targeted therapy and immunotherapy, etc; concurrent chemotherapy is not included. Note: Removal or biopsy of pelvic lymph nodes or para-aortic lymph nodes for the purpose of clinical staging is allowed).

3. Locally advanced cervical cancer(LACC): The International Federation of Gynecology and Obstetrics (FIGO) 2018 Stage IB3/IIA2, IIB-IVA.

7. At least one measurable tumor lesion according to RECIST v1.1 criteria.

8. Available archived tumor tissue samples or recent biopsies.

9. Adequate organ function.

10. For fertile women with negative serum pregnancy and effective contraception within 7 days before administration (until 120 days after the last administration of the study drug and at least 180 days after radiotherapy)

Exclusion Criteria:

1. Other histological types of cervical cancer (eg, neuroendocrine carcinoma, small cell carcinoma, sarcoma, etc).

2. Evidence of distant metastases.

3. Have received total hysterectomy.

4. Subject with other active malignancies within 2 years prior to randomization.

5. Subject who cannot receive brachytherapy.

6. Active or prior documented autoimmune disease that may relapse.

7. History of interstitial lung disease or noninfectious pneumonitis.

8. Subject with the clinically significant cardio-cerebrovascular disease.

9. History of severe hypersensitivity reactions to other mAbs.

10. Prior allogeneic stem cell transplantation or organ transplantation.

11. Subjects who require systemic treatment with glucocorticoid (>10 mg/day of prednisone or equivalent glucocorticoid) or other immunosuppressive agents within 14 days prior to randomization.

12. Receipt of live attenuated vaccines within 30 days prior to the first dose of the study drug.

13. Prior exposure to any experimental antitumor vaccines, or any agent targeting T-cell costimulation or immune checkpoint pathways (eg, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-CD137 or anti-OX40 antibody, etc).

14. Any condition that, in the opinion of the Investigator, would interfere with the evaluation of the study drug or interpretation of subject safety or study results.

Related Conditions & MeSH terms

• Locally Advanced Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Drug:
• Candonilimab(AK104)
q3w iv

Radiation:
• EBRT
45-50.4Gy
• BT
=80Gy

Locations

Country	Name	City	State
China	Chongqing university Cancer Hospital	Chongqing	CHN

Sponsors (2)

Lead Sponsor	Collaborator
Chongqing University Cancer Hospital	Akeso Pharmaceuticals, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR assessed by Investigator	The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR per RECIST v1.1.	Up to 2 years
Secondary	DCR	The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for =8 weeks) based on RECIST Version 1.1.	Up to 2 years
Secondary	PFS	Progression-free survival is defined as the time from the start of treatment with AK104 until the first documentation of disease progression or death due to any cause, whichever occurs first.	Up to approximately 30 months
Secondary	OS	OS is the time from randomization to death due to any cause	Up to approximately 40 months
Secondary	Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score and Physical Function Score.	The EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status. The change from baseline in EORTC QLQ-C30 score will be presented.	Baseline and up to approximately 40 months
Secondary	Number of participants with adverse events (AEs)	An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.	Up to approximately 40 months